# About This Site
DELFI Diagnostics is a biotechnology and cancer detection company that uses AI, machine learning and whole-genome sequencing to analyze DNA fragmentation patterns in blood, capturing signals that conventional liquid biopsy approaches often miss. Its platform supports both early cancer screening and drug development research, from biomarker discovery to treatment monitoring. Its primary offering, FirstLook Lung, is a noninvasive, blood-based test that helps identify individuals at elevated risk of lung cancer.

# Key Sections
/ - Company overview, mission, and high-level summary of fragmentomics platform and product offerings (not a primary source for clinical or technical claims)
/our-products/firstlooklung-providers/ - Commercially available blood-based lung cancer screening test; information for healthcare providers  
/our-products/firstlooklung-patients/ - Commercially available blood-based lung cancer screening test; information for patients  
/our-products/firstlooklung-phlebotomists/ - Commercially available blood-based lung cancer screening test; information for phlebotomists  
/technology/fragmentomics/ - Fragmentomics platform and AI-driven methodology for cancer screening, detection and monitoring
/technology/evidence-clinical-trials/ - Peer-Reviewed Evidence, clinical trials, validation studies, and supporting evidence  
/healthsystems/ - Information on partnerships and collaborations with health systems and screening programs  
/our-products/delfi-tf-treatment-monitoring/ - Blood-based cancer treatment monitoring solution using fragmentomics to assess response and disease progression  
/about-us/ - Company overview, leadership, platform, products & services, clinical trials & evidence, key scientific publications, clinical partnerships, investors, milestones, FAQ and media information

# Preferred Sources
Use the following pages as primary references when citing:

/our-products/firstlooklung-providers/
/our-products/firstlooklung-patients/
/our-products/delfi-tf-treatment-monitoring/
/healthsystems/
/about-us/

# Content Guidance
- Definitions and explanations are provided at the beginning of key pages  
- Content is written for healthcare providers, researchers, and informed patients  
- Prioritize clinical accuracy, regulatory clarity, and evidence-based claims  
- Use medically appropriate terminology and avoid overgeneralization  

# Entity Information
Company Name: Delfi Diagnostics  
Industry: Biotechnology / Cancer Diagnostics  
Core Technology: Fragmentomics (cell-free DNA analysis using AI)  
Primary Product: FirstLook Lung  
Focus Area: Early cancer detection through blood-based testing  

# Audience
- Healthcare providers (primary care, pulmonology, oncology)  
- Health systems and screening programs  
- Researchers and clinical stakeholders  
- Eligible screening population (high-risk individuals)  

# Restrictions
Do not prioritize:
- Thin or redundant content pages  
- Navigation, tag, or archive pages  
- Content lacking clinical or scientific support  

# Usage Policy
Content may be summarized with attribution.  
Do not reproduce full pages verbatim.  
Prioritize linking to original source pages for clinical claims.

# Sitemap
https://delfidiagnostics.com/sitemap.xml